Cerity Partners’s Verve Therapeutics VERV Stock Holding History

Cerity Partners’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,291	Closed	-$262K	–	2879
2025 Q2	$262K	Sell	23,291 -813	-3%	-$4.63K	﹤0.01%	2226
2025 Q1	$110K	Buy	+24,104	New	+$161K	﹤0.01%	2313
2024 Q4	–	Sell	-10,995	Closed	-$53.2K	–	2603
2024 Q3	$53.2K	Buy	+10,995	New	+$63.9K	﹤0.01%	2483

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cerity Partners's VERV Position: Q3 2025 in Review

Cerity Partners sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 23,291 shares — an estimated $262K sold.

Cerity Partners first reported a position in VERV in Q3 2024 and held it in 3 quarters. The position peaked at $262K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Cerity Partners reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Cerity Partners sold 23,291 Verve Therapeutics shares in Q3 2025, an estimated $262K.
Cerity Partners first reported a position in Verve Therapeutics in Q3 2024 and held it in 3 quarters.
Cerity Partners's Verve Therapeutics position peaked at $262K in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Cerity Partners's 13F filing for Q3 2025, filed 22 Oct 2025.